ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
-5.07%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$262M
AUM Growth
+$262M
(-21%)
Cap. Flow
-$50.9M
Cap. Flow
% of AUM
-19.42%
Top 10 Holdings %
Top 10 Hldgs %
60.55%
Holding
81
New
18
Increased
11
Reduced
15
Closed
31
Top Buys
| 1 |
Qiagen
QGEN
|
$16.2M |
| 2 |
Boston Scientific
BSX
|
$15.6M |
| 3 |
Icon
ICLR
|
$10.8M |
| 4 |
Zoetis
ZTS
|
$7.07M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$5.82M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$15.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
$14.2M |
| 3 |
Orthofix Medical
OFIX
|
$14.2M |
| 4 |
Centene
CNC
|
$12.7M |
| 5 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
$9.98M |
Sector Composition
| 1 | Healthcare | 76.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Qiagen
QGEN
$10.1B
| $18.8M | 6.59% | 398,221 +342,565 | +616% | +$16.2M |
|
|
2
Boston Scientific
BSX
$156B
| $15.6M | 5.47% | +418,165 | New | +$15.6M |
|
3
Avantor
AVTR
$9.18B
| $14M | 4.92% | 450,821 +164,920 | +58% | +$5.13M |
|
4
Humana
HUM
$36.5B
| $12.7M | 4.45% | 27,106 -2,014 | -7% | -$943K |
|
|
5
Icon
ICLR
$13.8B
| $10.8M | 3.78% | +49,718 | New | +$10.8M |
|
6
Cigna
CI
$80.3B
| $10.6M | 3.73% | 40,372 +11,655 | +41% | +$3.07M |
|
7
Hologic
HOLX
$14.9B
| $8.85M | 3.1% | 127,656 +4,032 | +3% | +$279K |
|
8
Labcorp
LH
$23.1B
| $8.14M | 2.85% | 34,718 -26,561 | -43% | -$6.23M |
|
9
Elutia
ELUT
$96.7M
| $8.01M | 2.81% | 1,133,183 +23,704 | +2% | +$168K |
|
10
Bio-Rad Laboratories Class A
BIO
$8.06B
| $7.93M | 2.78% | 16,028 -1,123 | -7% | -$556K |
|
|
11
Zoetis
ZTS
$69.3B
| $7.07M | 2.48% | +41,100 | New | +$7.07M |
|
12
Cartesian Therapeutics
RNAC
$261M
| $6.04M | 2.12% | 4,611,635 +1,159,677 | +34% | +$1.52M |
|
|
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.82M | 2.04% | +32,871 | New | +$5.82M |
|
|
14
Centene
CNC
$14.3B
| $5.78M | 2.03% | 68,305 -149,930 | -69% | -$12.7M |
|
15
Baxter International
BAX
$12.7B
| $5.77M | 2.02% | +89,863 | New | +$5.77M |
|
16
SI-BONE Inc
SIBN
$719M
| $5.68M | 1.99% | 430,159 +16,789 | +4% | +$222K |
|
17
McKesson
MCK
$85.4B
| $5.21M | 1.83% | 15,984 -13,184 | -45% | -$4.3M |
|
18
Teva Pharmaceuticals
TEVA
$21.1B
| $3.46M | 1.21% | +459,829 | New | +$3.46M |
|
|
ADAP
19
Adaptimmune Therapeutics
ADAP
$15.6M
| $3.1M | 1.09% | 1,824,065 -336,825 | -16% | -$573K |
|
20
Ocular Therapeutix
OCUL
$2.12B
| $3.06M | 1.07% | 760,228 -163,735 | -18% | -$658K |
|
21
Galapagos
GLPG
$2.07B
| $2.87M | 1.01% | 51,410 -990 | -2% | -$55.2K |
|
22
Insmed
INSM
$28.8B
| $2.8M | 0.98% | 142,071 -23,209 | -14% | -$458K |
|
23
Neurocrine Biosciences
NBIX
$13.8B
| $2.73M | 0.96% | +27,992 | New | +$2.73M |
|
|
GBT
24
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $2.59M | 0.91% | 81,007 +37,757 | +87% | +$1.21M |
|
25
Tenet Healthcare
THC
$16.3B
| $2.49M | 0.87% | 47,442 -83,934 | -64% | -$4.41M |
|